WASHINGTON DC. WA, September 25, 2026 — The cost to the United States of Alzheimer’s disease alone will reach $818 billion this year. Much of that burden, however, falls not on formal healthcare spending but rather on unpaid family caregivers — a new study discovers. The findings are reviving calls for the quicker development of effective treatments.
The Financial Burden Scale
The new estimate comes from a study by researchers at the University of Southern California. It found that a significant proportion is patient and family caregiver hidden costs. About seven million Americans are now living with Alzheimer’s disease or similar dementias.
And that number is anticipated to be nearly doubled, by 2050 when the population grows older. Unless we are able to experience some significant breakthroughs on the medical side, costs will only continue to rise — and not just by a little bit either, according to a study from USC Schaeffer Center. Medicare and Medicaid spending for dementia care are also anticipated to increase significantly.
The high cost of some new drugs remains a thorny issue with no simple answers
Our study focused on two FDA-approved treatments: the amyloid-clearing drug donanemab and lecanemab. Donanemab comes in at around $32,000 a year and lecanemab hovers right around $26,500 annually. Both need frequent infusions and brain scans at various intervals to check for side-effects.
This word of development costs partly explains why these therapies come with such high price tags. In a span of more than 20 years, few new Alzheimer’s drugs have been approved. Over that time, researchers have estimated, the private sector has poured billions of dollars into studying the disease.
The Push for Better Options
Health policy experts contend that the number of approved drugs can ultimately lead to lower prices. Historically, the increased competition in the treating market has resulted in ever reducing prices over time. Researchers are also investigating ways to detect them earlier — seeing them nanoseconds before they strike could certainly bolster treatment methods.
Later therapies focus on inflammation and tau protein build up apart from simply amyloid plaques. Numerous agents using such approaches are presently in clinical evaluation. The final twist is that broadening treatment targets could provide better results for a bigger swath of patients, say advocates.
The Toll on Family Caregivers
These unpaid caregivers often absorb costs that are not reflected in standard health care spending statistics. This consists of missing earnings, decreased working hours and the toll on physical fitness long-term. This burden was inaccurately acknowledged over the years, as noted in the USC-led study.
Advocacy Groups Urge Lawmakers to Provide Direct Family Caregiver Support Programs
It includes state tax credits and additional funding for respite care. It is unclear whether Congress will take any action on these proposals as it heads into its fall session.
What patients and their families should know
One of the most powerful tools we currently have to manage the disease is an early diagnosis. Early diagnosis may allow patients to receive newer treatments aimed at slowing disease progression. Doctors worry families who notice changes in memory should get evaluated sooner than later.
Even when treatment is medically indicated, cost continues to be a major obstacle for many patients. Insurance coverage differs substantially depending upon a person’s patient plan and stage of diagnosis. And advocates say increasing affordable access will be one of the major keys to controlling the rising cost of potential treatments for the disease.
The researchers also highlight the importance of lifestyle in lowering dementia risk over the long-term. Exercise, socialisation and controlling for cardiovascular health have all been found to be protective in the literature. With new drug development, prevention efforts could help significantly reduce future expenditures according to public health officials.
With many workers juggling dual roles, employers are also starting to feel the burden of caregiving. In response, some companies have begun to give flexible scheduling or caregiver support benefits. As the caregiving population continues to grow, advocates hope that this will translate into more sweeping workplace policies.
In the next few years, we will more likely see more clinical trial results from new treatment modalities. Whether any of them have a substantial impact on lowering costs has yet to be determined, researchers say. In any event, the ongoing financial and emotional burden of surviving with the ailment cannot be overstated for families coping with it as we speak.
